Long‐term efficacy and safety of galantamine in patients with mild‐to‐moderate Alzheimer's disease: multicenter trial
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In clinical trials, short‐term galantamine treatment produces consistent positive effects on global ratings, cognitive tests, and assessments of activities of daily living and behavior in patients with mild‐to‐moderate Alzheimer's disease (AD), providing the rationale for longer‐term, open‐label treatment. In this continuation trial following enrollment in previous 12‐month trials, patients received galantamine 24 mg/day for a total of 24 months (total exposure up to 36 months). Primary efficacy measures were the ADAS‐cog/11 and DAD. Adverse events (AEs) were coded to WHO preferred terms, including AEs begun in previous trials. Initial improvement in cognitive function was followed by a gradual decline, as measured by increased ADAS‐cog/11 scores. At 36 months, ADAS‐cog/11 scores increased by a mean (SEM) of 12.4 (0.80) points (P < 0.001) versus a projected 22‐point increase for untreated patients. Functional abilities, as measured by the DAD, had decreased significantly at each time point versus baseline (P < 0.001). The most common treatment‐emergent AEs were agitation (16.1%), insomnia (12.4%), fall (11.2%), and urinary tract infection (10.2%). AEs were mainly mild to moderate, appropriate for an elderly population, with few judged treatment related. Galantamine 24 mg/day is safe and effective for long‐term treatment of mild‐to‐moderate AD. Potential exists for prolonged benefit with galantamine therapy versus lack of treatment for the long‐term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 1×
“Brain biopsies and autopsy studies have demonstrated that patients with AD have reduced activity of cortical choline acetyltransferase and degeneration of acetylcholine-producing neurons in the nucleus basalis of Meynert (Davies and Maloney, 1976; Whitehouse et al., 1981).”
BackgroundAlzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408
Cited by
Drug discovery from medicinal plants
Balunas, M. J., & Kinghorn, A. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.012 · Cited by 1,810
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Plant derived substances with anti-cancer activity: from folklore to practice
Fridlender, M., Kapulnik, Y., & Koltai, H. (2015) · Frontiers in Plant Science · doi:10.3389/fpls.2015.00799 · Cited by 415
Wilkinson, D. G., Francis, P. T., Schwam, E., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 365
Metadata
- Authors
- Pirttilä, T., Wilcock, G., Truyen, L., & Damaraju, C. V.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2004-11
- Volume
- 11
- Issue
- 11
- Pages
- 734-741
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2168891350
- Cited by
- 92
- References
- 4
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term efficacy and safety of galantamine in patients with mild‐to‐moderate Alzheimer's disease: multicenter trial. https://app.cochat.ai/papers/10.1111/j.1468-1331.2004.00885.x
- The paper
- Pirttilä, T., Wilcock, G., Truyen, L., & Damaraju, C. V. (2004). Long‐term efficacy and safety of galantamine in patients with mild‐to‐moderate Alzheimer's disease: multicenter trial. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2004.00885.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.